A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Exclusion Criteria

• •Participants currently receiving treatment for a non-APL malignancy (not including basal cell carcinoma, non-melanoma skin cancer, cervical carcinoma in situ, or localized prostate cancer treated with hormone therapy). Participants with history of other cancers should be free of disease for at least 2 years prior to the Screening Visit.
• •Participants with an active, life-threatening, or clinically-significant uncontrolled systemic infection requiring hospitalization.
• •Immunocompromised participants with increased risk of opportunistic infections, including known human immunodeficiency virus (HIV)-positive participants with cluster of differentiation 4 (CD4) counts ≤350 cells/millimeters (mm\^3) or history of opportunistic infection in the last 12 months.
• •Participants with a known active or chronic hepatitis B or active hepatitis C virus (HCV) infection. Participants with a history of HCV infection who have completed curative therapy for HCV at least 12 weeks before the Screening Visit and have a documented undetectable viral load at the Screening Visit are eligible for enrollment.
• •Participants who have not adequately recovered from a major surgery within 4 weeks of starting study drug administration.
• •Participants who received any other investigational agents within 4 weeks of the Screening Visit or \<5 half-lives since completion of previous investigational therapy have elapsed, whichever is shorter.
• •Participants who have a hypersensitivity to arsenic.
• •Participants who have experienced the following Grade ≥3 non-hematologic toxicities associated with ATO administration: QT prolongation, hepatotoxicity, neurotoxicity, cardiac function abnormalities. Participants who experienced other severe and life-threatening clinically-significant ATO-related AEs that are considered, in the judgement of the investigator, to increase participant risk with continued ATO treatment are also excluded.